CytoDyn’s PRO 140 monoclonal antibody prevents GvHD in model of none marrow
Newly published research provides preclinical proof-of-concept for the ability of PRO 140, a humanized anti-CCR5 monoclonal antibody under development by CytoDyn, to effectively block the development of GvHD, a potentially lethal complication of BMSC transplantation. November 14, 2017